An <scp>SGLT2</scp> inhibitor, canagliflozin, reduces blood glucose level in the renal capillaries and protects the capillary network in the diabetic rats
These findings indicate that canagliflozin offers superior protection of the renal microvasculature from hyperglycaemic stress, independent of its systemic glucose-lowering action.
Authors
- Satoshi Kidoguchi (ORCID: https://orcid.org/0000-0001-8114-8952)
- Daisuke Nakano (ORCID: https://orcid.org/0000-0002-7435-8465)
- Akira Nishiyama (ORCID: https://orcid.org/0000-0001-5971-820X)
- Xiao Hu (ORCID: https://orcid.org/0000-0003-1128-4099)
- Ashley Zhang (ORCID: https://orcid.org/0009-0000-0753-0838)
- Bi Zhichen
Institutions
- Capital Medical University (CN)
- Kagawa University (JP)
- Beijing Chao-Yang Hospital, Capital Medical University (CN)
- Capital Institute of Pediatrics (CN)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-09-10
- DOI
- https://doi.org/10.1111/dom.70118
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Beijing Postdoctoral Science Foundation
- Mitsubishi Tanabe Pharma Corporation